Ascendis Pharma A/S (NASDAQ:ASND) Shares Purchased by Nomura Asset Management Co. Ltd.

Nomura Asset Management Co. Ltd. grew its position in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 42.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 18,000 shares of the biotechnology company’s stock after acquiring an additional 5,371 shares during the quarter. Nomura Asset Management Co. Ltd.’s holdings in Ascendis Pharma A/S were worth $2,688,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Janus Henderson Group PLC raised its stake in shares of Ascendis Pharma A/S by 6.8% in the 3rd quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock valued at $625,075,000 after acquiring an additional 267,881 shares during the period. Avoro Capital Advisors LLC lifted its stake in shares of Ascendis Pharma A/S by 5.8% during the second quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock worth $572,341,000 after purchasing an additional 229,995 shares in the last quarter. Westfield Capital Management Co. LP lifted its stake in shares of Ascendis Pharma A/S by 3.4% during the third quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock worth $766,523,000 after purchasing an additional 170,942 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of Ascendis Pharma A/S by 9.1% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock worth $278,760,000 after buying an additional 155,971 shares during the period. Finally, Fred Alger Management LLC grew its stake in shares of Ascendis Pharma A/S by 65.0% in the second quarter. Fred Alger Management LLC now owns 307,073 shares of the biotechnology company’s stock valued at $41,879,000 after buying an additional 120,952 shares in the last quarter.

Ascendis Pharma A/S Stock Down 0.6 %

Shares of NASDAQ ASND opened at $129.87 on Friday. The stock’s 50 day moving average price is $129.15 and its two-hundred day moving average price is $132.72. Ascendis Pharma A/S has a 52-week low of $111.09 and a 52-week high of $161.00. The stock has a market capitalization of $7.88 billion, a P/E ratio of -16.07 and a beta of 0.67.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Citigroup upped their price target on Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th. Wells Fargo & Company upped their target price on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an “overweight” rating in a research note on Tuesday, September 17th. StockNews.com raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Bank of America upped their price objective on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. Finally, Evercore ISI lifted their target price on Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 17th. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $191.77.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.